Sodium Bicarbonate Injection

1. Treat metabolic acidosis. This product increases the concentration of carbonate in plasma, neutralizes hydrogen ions, and corrects acidosis. 2. Alkalinizes urine. As the concentration of carbonate in urine increases, the pH value increases, making it difficult for uric acid, sulfonamide drugs, and hemoglobin to form crystals or aggregate in urine. 3. Antacid. Oral administration can quickly neutralize or buffer gastric acid without directly affecting gastric acid secretion. Therefore, the pH in the stomach increases rapidly to relieve symptoms caused by high gastric acid.

The main ingredients of this product: Sodium bicarbonate Chemical name: Sodium bicarbonate Molecular formula: NaHCO3 Molecular weight: 84.01 Auxiliary materials: Disodium edetate

This product is a colorless clear liquid.

1 Treatment of metabolic acidosis: For the treatment of mild to moderate metabolic acidosis, oral administration is preferred; for severe metabolic acidosis, intravenous drip should be used, such as in severe kidney disease, circulatory failure, cardiopulmonary resuscitation, extracorporeal circulation, severe primary lactic acidosis, diabetic ketoacidosis, etc. 2 Alkalinize urine: used for the prevention of uric acid kidney stones, reducing the nephrotoxicity and acute hemolysis of sulfonamides, and preventing hemoglobin deposition in the renal tubules. 3 As an antacid, it treats symptoms caused by excessive gastric acid. 4 Intravenous drip has a non-specific therapeutic effect on certain drug poisonings, such as poisoning by barbiturates, salicylates and methanol. However, this product is contraindicated for gastric lavage in case of ingestion of strong acid poisoning, because

Metabolic acidosis, intravenous drip, the required dose is calculated according to the following formula: Alkali supplement amount (mmol) = (-2.3 - actual measured BE value) × 0.25 × body weight (kg), or alkali supplement amount (mmol) = normal CO2CP - actual measured CO2CP (mmol) × 0.25 × body weight (kg). Unless the body loses bicarbonate, generally 1/3 to 1/2 of the calculated dose is given first, and the drip is completed within 4 to 8 hours. During cardiopulmonary resuscitation, the first dose is 1mmol/kg, and the dosage is adjusted according to the results of blood gas analysis (each 1g of sodium bicarbonate is equivalent to 12mmol bicarbonate). The following issues should also be noted for intravenous medication: ① The concentration range for intravenous application is 1.5% (isotonic) to 8.4%; ② It should start with a small dose, according to the blood

1. Arrhythmia, muscle cramps, pain, abnormal fatigue and weakness may occur when a large amount of injection is given, mainly due to hypokalemia caused by metabolic alkalosis. 2. Edema, mental symptoms, muscle pain or convulsions, slowed breathing, bad breath, abnormal fatigue and weakness may occur when the dose is too large or there is renal insufficiency. Mainly caused by metabolic alkalosis. 3. Long-term use may cause frequent urination, urgent urination, persistent headache, loss of appetite, nausea and vomiting, abnormal fatigue and weakness, etc.

Not yet clear.

Precautions for children: For the treatment of acidosis, refer to the adult dose. During cardiopulmonary resuscitation, the first intravenous injection is 1mmol/kg of body weight, and the dosage is adjusted according to the results of blood gas analysis. Precautions for pregnancy and lactation: 1. Long-term or large-scale use can cause metabolic alkalosis, and excessive sodium load can cause edema, etc. Pregnant women should use it with caution. 2. This product can be secreted through breast milk, but there is no relevant information on its effects on infants. Precautions for the elderly: This experiment has not been conducted and there are no reliable references.

1. When used in combination with adrenocortical hormones (especially those with strong mineralocorticoid effects), adrenocorticotropic hormones, and androgens, hypernatremia and edema are likely to occur. 2. When used in combination with amphetamine and quinidine, the renal excretion of the latter two is reduced, and toxic effects are likely to occur. 3. When used in combination with anticoagulants such as warfarin and M cholinesterase drugs, the absorption of the latter is reduced. 4. When used in combination with calcium-containing drugs, milk and dairy products, milk-alkali syndrome may occur. 5. When used in combination with H2 receptor antagonists such as cimetidine and ranitidine, the absorption of the latter is reduced. 6. When used in combination with potassium-excreting diuretics, the risk of hypochloremic alkalosis is increased.

Store in airtight container. Valid for 36 months.

10ml:0.5g